Company Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage.
Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Aug 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 126 |
| CEO | Dinesh Patel |
Contact Details
Address: 7707 Gateway Boulevard, Suite 140 Newark, California 94560 United States | |
| Phone | 510 474 0170 |
| Website | protagonist-inc.com |
Stock Details
| Ticker Symbol | PTGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001377121 |
| CUSIP Number | 74366E102 |
| ISIN Number | US74366E1029 |
| Employer ID | 98-0505495 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dinesh V. Patel Ph.D. | Chief Executive Officer, President, Secretary and Director |
| Asif Ali | Executive Vice President and Chief Financial Officer |
| Dr. Suneel K. Gupta Ph.D. | Executive Vice President of Clinical Development |
| Dr. Arturo M. Molina FACP, M.D., M.S. | Chief Medical Officer |
| Mohammad Masjedizadeh Ph.D. | Executive Vice President and Chief Technology Officer |
| Dr. Newman Yeilding | Executive Vice President, Chief Scientific Officer |
| Matthew M. Gosling J.D. | Executive Vice President and General Counsel |
| Carena Spivey | Head of Human Resources and Senior Vice President of Human Resources |
| Dr. Ashok Bhandari Ph.D. | Executive Vice President and Chief Discovery Officer |
| Carter J. King | Executive Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | SCHEDULE 13G | Filing |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2025 | SCHEDULE 13G/A | Filing |
| Apr 10, 2025 | SCHEDULE 13G | Filing |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 144 | Filing |